Ulman L G, Potter E K, McCloskey D I
Prince of Wales Medical Research Institute, Prince of Wales Hospital, Randwick, Sydney, Australia.
Regul Pept. 1994 Apr 14;51(1):17-23. doi: 10.1016/0167-0115(94)90130-9.
Previous studies have shown that injection of galanin (GAL: 6.2 nmol/kg) causes prolonged inhibition of cardiac vagal action in anaesthetised cats. Stimulation of the cardiac sympathetic nerve (16 Hz for 5 min) also produces inhibition of cardiac vagal action, an effect which has been proposed to be due to the release of endogenous GAL from sympathetic nerves. In a previous study we tested galantide (M15) and in this study we compared galantide with two other GAL antagonists for their GAL antagonist activity in our experimental model. Each of these incorporate the N-terminal fragment GAL 1-13 and a C-terminal portion of another bioactive peptide and all are C-terminally amidated. GAL 1-13 Substance P 5-11 amide (galantide: M15: 62 nmol/kg and 156 nmol/kg), GAL 1-13 Spantide amide (C7: 156 nmol/kg) and GAL 1-13 NPY 24-36 amide (M32a: 62 nmol/kg) all significantly reduced the cardiac vagal inhibitory effect of exogenous GAL and also reduced the effect of sympathetic stimulation on subsequent cardiac vagal slowing, giving strong support to our hypothesis that GAL is involved in this phenomenon. No antagonist reduced the depressor effect of GAL. This study demonstrates the GAL antagonist properties of these agents on autonomic neuroeffector functions making them useful tools in elucidating further functions of endogenous GAL.
先前的研究表明,注射甘丙肽(GAL:6.2 nmol/kg)会导致麻醉猫的心脏迷走神经作用受到长时间抑制。刺激心脏交感神经(16 Hz,持续5分钟)也会产生心脏迷走神经作用的抑制,有人提出这种作用是由于交感神经释放内源性GAL所致。在之前的一项研究中我们测试了加兰他敏(M15),在本研究中我们将加兰他敏与另外两种GAL拮抗剂在我们的实验模型中进行了GAL拮抗剂活性的比较。这些拮抗剂均包含N端片段GAL 1-13和另一种生物活性肽的C端部分,并且均在C端酰胺化。GAL 1-13 P物质5-11酰胺(加兰他敏:M15:62 nmol/kg和156 nmol/kg)、GAL 1-13 斯帕坦酰胺(C7:156 nmol/kg)和GAL 1-13 神经肽Y 24-36酰胺(M32a:62 nmol/kg)均显著降低了外源性GAL的心脏迷走神经抑制作用,并且也降低了交感神经刺激对随后心脏迷走神经减慢的作用,有力地支持了我们关于GAL参与此现象的假设。没有拮抗剂降低GAL的降压作用。本研究证明了这些药物对自主神经效应器功能的GAL拮抗剂特性,使其成为阐明内源性GAL进一步功能的有用工具。